Product
Supplier
Encyclopedia
Inquiry
Jinlan 98+ EP/BP/USP Relugolix buy - large image1
Jinlan 98+ EP/BP/USP Relugolix buy - image1

Jinlan 98+ EP/BP/USP Relugolix

5 Inquiries

Unit Price: Get Latest Price
CAS No.:

737789-87-6

Grade:

medical grade

Content:

98%

Port:

Shanghai/Ningbo/Qingdao

Brand:

Jinlan

Packaging:

25kg/Cardboard Drum

Price valid (until):

2026-04-01

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Peptides,API,Intermediate

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Relugolix
    CAS No.: 737789-87-6
    Molecular Formula: C₂₄H₂₆N₄O₂
    Molecular Weight: 394.48
    EINECS No.: Not available
    Related Categories: GnRH Antagonists; Hormonal Therapeutics; Small Molecule Inhibitors; Heterocyclic Compounds; Pyridines; Pharmaceutical Intermediates
    Mol File: 737789-87-6.mol

    Basic Info
    Product Name:

    Relugolix

    Other Name:

    Relugolix;Altropane;TKA-385 Relugolix;1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea;Relugolix TAK-385;TAK-385,Relugolix;CS-2851;TAK-385;TAK 385;TAK385

    CAS No.:

    737789-87-6

    Molecular Formula:

    C29H27F2N7O5S

    InChIKeys:

    AOMXMOCNKJTRQP-UHFFFAOYSA-N

    Molecular Weight:

    623.63

    Exact Mass:

    623.63

    EC Number:

    237-099-7

    UNII:

    P76B05O5V6

    DSSTox ID:

    DTXSID40224167

    NCI Thesaurus Code:

    C114498

    Color/Form:

    White to off-white

    ATC Code:

    H01CC54

    Categories:

    Other Chemical Drugs

    Characteristics
    Density:

    1.442±0.06 g/cm3(Predicted)

    Melting Point:

    228 °C (decomp)(Solv: ethyl acetate (141-78-6); tetrahydrofuran (109-99-9))

    PKA:

    13.17±0.70(Predicted)

    Critical Temperature & Pressure:

    Store at -20°C

    Hazard Identification

    Classification of the substance or mixture

    no data available

    GHS label elements, including precautionary statements

    Pictogram(s) no data available
    Signal word

    no data available

    Hazard statement(s)

    no data available

    Precautionary statement(s)
    Prevention

    no data available

    Response

    no data available

    Storage

    no data available

    Disposal

    no data available

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,API,Intermediate

    Location:

    Room 606, Building 1, Fu Yi Commercial Center, Shangcheng District, Hangzhou City, Zhejiang Province - 1

    Payment Terms:

    100% TT in advance

    Average lead Time:

    275

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2020

    Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int' l Airport and Shanghai Pudong Int' l Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, CMO, CRO, CDMO and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on.

    JINLAN PHARM focus on:

    ■ Contrast Agent

    ■ Anti-COVID APIs

    ■ Respiratory System APIs

    ■ Anti-tumor & Anti-Cancer APIs

    ■ Anti-Diabetes APIs

    ■ Anti-HCV & Anti-HBV APIs

    ■ Anti-HIV APIs

    ■ Peptides

    ■ Pharmaceutical Intermediates

    ■ CMO, CRO, CDMO

  • Inquiry History
    5 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    99% Pharmacy Grade Relugolix

    100 G Nov 30, 2025
    Greece

    Relugolix tablets

    120 MG Nov 14, 2025
    Bangladesh

    RELUGOLIX

    1 20' Fcl Dec 12, 2025
    Greece

    Relugolix tablets

    120 MG Nov 14, 2025
    United States

    Relugolix

    10 G Sep 15, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.